In this study, we identified the optimal protocol for a PI3K inhibitor ZSTK474 in combination with anti-PD-1 mAb with which a far stronger antitumor immune responses were induced with selective Treg suppression and activation of tumor antigen-specific CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.